123 related articles for article (PubMed ID: 15197517)
1. Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects.
Sabia H; Sunkara G; Ligueros-Saylan M; Wang Y; Smith H; McLeod J; Prasad P
Eur J Clin Pharmacol; 2004 Aug; 60(6):407-12. PubMed ID: 15197517
[TBL] [Abstract][Full Text] [Related]
2. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
Niemi M; Backman JT; Juntti-Patinen L; Neuvonen M; Neuvonen PJ
Br J Clin Pharmacol; 2005 Aug; 60(2):208-17. PubMed ID: 16042675
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.
Cheng Y; Wang G; Zhang W; Fan L; Chen Y; Zhou HH
Eur J Clin Pharmacol; 2013 Mar; 69(3):407-13. PubMed ID: 22842957
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
5. A 3-way crossover study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers.
Anderson DM; Shelley S; Crick N; Buraglio M
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):457-64. PubMed ID: 12395978
[TBL] [Abstract][Full Text] [Related]
6. The effect of nateglinide taken with food on gastric emptying rates in healthy subjects.
Anderson D; Shelley S; Kellett N; Marshall D; Nimmo W
Clin Ther; 2003 Jun; 25(6):1722-38. PubMed ID: 12860494
[TBL] [Abstract][Full Text] [Related]
7. No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers.
Anderson DM; Shelley S; Crick N; Buraglio M
J Clin Pharmacol; 2002 Dec; 42(12):1358-65. PubMed ID: 12463731
[TBL] [Abstract][Full Text] [Related]
8. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects.
Niemi M; Backman JT; Neuvonen M; Neuvonen PJ
Br J Clin Pharmacol; 2003 Oct; 56(4):427-32. PubMed ID: 12968988
[TBL] [Abstract][Full Text] [Related]
9. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
Sunkara G; Bigler H; Wang Y; Smith H; Prasad P; McLeod J; Ligueros-Saylan M
Curr Med Res Opin; 2004 Jan; 20(1):41-8. PubMed ID: 14741071
[TBL] [Abstract][Full Text] [Related]
10. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Scheen AJ
Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
[TBL] [Abstract][Full Text] [Related]
11. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.
Karara AH; Dunning BE; McLeod JF
J Clin Pharmacol; 1999 Feb; 39(2):172-9. PubMed ID: 11563410
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of nateglinide in renally impaired diabetic patients.
Devineni D; Walter YH; Smith HT; Lee JS; Prasad P; McLeod JF
J Clin Pharmacol; 2003 Feb; 43(2):163-70. PubMed ID: 12616669
[TBL] [Abstract][Full Text] [Related]
13. Effect of fluvastatin, lovastatin, nifedipine and verapamil on the systemic exposure of nateglinide in rabbits.
Kim Y; Park K; Kang W
Biopharm Drug Dispos; 2010 Nov; 31(8-9):443-9. PubMed ID: 20809476
[TBL] [Abstract][Full Text] [Related]
14. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
J Clin Pharmacol; 2008 Mar; 48(3):311-21. PubMed ID: 18187595
[TBL] [Abstract][Full Text] [Related]
15. Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide.
Niemi M; Neuvonen M; Juntti-Patinen L; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2003 Jul; 74(1):25-31. PubMed ID: 12844132
[TBL] [Abstract][Full Text] [Related]
16. Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis.
Choudhury S; Hirschberg Y; Filipek R; Lasseter K; McLeod JF
J Clin Pharmacol; 2000 Jun; 40(6):634-40. PubMed ID: 10868314
[TBL] [Abstract][Full Text] [Related]
17. Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
Luzio SD; Anderson DM; Owens DR
J Clin Endocrinol Metab; 2001 Oct; 86(10):4874-80. PubMed ID: 11600556
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and metabolism of nateglinide in humans.
Weaver ML; Orwig BA; Rodriguez LC; Graham ED; Chin JA; Shapiro MJ; McLeod JF; Mangold JB
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):415-21. PubMed ID: 11259325
[TBL] [Abstract][Full Text] [Related]
19. Prediction of the metabolic interaction of nateglinide with other drugs based on in vitro studies.
Takanohashi T; Koizumi T; Mihara R; Okudaira K
Drug Metab Pharmacokinet; 2007 Dec; 22(6):409-18. PubMed ID: 18159128
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure.
Inoue T; Shibahara N; Miyagawa K; Itahana R; Izumi M; Nakanishi T; Takamitsu Y
Clin Nephrol; 2003 Aug; 60(2):90-5. PubMed ID: 12940610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
